XpresSpa Group reported $9.1 million in total revenue, including $8.7 million from XpresCheck, and significantly reduced its Adjusted EBITDA loss and net loss compared to the previous year. The company is expanding its services with the Treat brand and re-opening legacy XpresSpa locations.
MSA practice patient fees increased to $17.1 million in Q2 from $6.3 million in Q1.
Net loss narrowed to $4.7 million compared to $58.5 million in the prior year's second quarter.
Strong liquidity position with an unrestricted cash balance of $102.5 million.
Launched Phase 2 of Treat™ and plans to launch Phase 3 this fall.
The company is focused on expanding its three sustainable growth brands, leveraging its corporate structure and airport relationships to increase market share and shareholder value.
Analyze how earnings announcements historically affect stock price performance